As we age, our bodies produce less glutathione, which can lead to various health concerns
(Source: The World Data, April 2026) Tirzepatide Health Benefits Beyond Weight Loss Like semaglutide, the clinical evidence for tirzepatide extends well beyond weight loss
Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1
For example, Novo Nordisk launched its Wegovy pill earlier this year, while Eli Lillys oral GLP-1, orforglipron (orfo), is expected to receive final Food and Drug Administration (FDA) approval in April
Individuals aiming for weight loss or even those interested in substantial weight gain (bulking) can find glycemic control to be immensely helpful